Pre-malignant States to Hematologic Malignancies in Firefighters

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT06870760
Status
Recruiting
Apply to this trial

Conditions

  • Clonal Hematopoiesis of Indeterminate Potential
  • Leukemia
  • Monoclonal Gammopathy
  • Multiple Myeloma
  • Non Hodgkin Lymphoma
  • Plasma Cell Disorder

Eligibility Criteria

Sex
ALL
Age
40 Years - 49 Years
Healthy Volunteers
Accepted

Interventions

  • Monoclonal Gammopathy — OTHER
    Whole blood will be collected at the Baseline visit to evaluate for monoclonal gammopathy through SPEP, immunofixation, and free light chains.
  • Complete Blood Count with differential (CBC w/ diff) — OTHER
    Whole blood will be collected at the Baseline visit for CBC with differential which may inform a diagnosis of a plasma cell disorder or other hematological disorder.
  • Clonal hematopoiesis (CHIP) — OTHER
    Whole blood will be collected at the Baseline visit to be evaluated using next generation sequencing (NGS) detection of CHIP. Deep NGS to identify mutations associated with myeloid neoplasms and CHIP will be performed using an error-correcting next generation sequencing multi-gene panel targeting genes most frequently mutated in CHIP.

Study Details

The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.

Key Dates

Start date
Jun 30, 2026
Status verified
Apr 2026
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Firefighter
    Participants employed by the Charlotte Fire Department (CFD) with at least 5 years of on-the-job experience between the ages of 40 and 49

Primary Outcome Measure

Clonal Hematopoiesis (CHIP) [ Time Frame: From enrollment to availability of lab results, approximately 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Levine Cancer InstituteCharlotteNorth Carolina28204
Megan Lattanze
[email protected]
980-442-4239
Larry Druhan, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Charlotte, NC

By condition
Leukemia (other)Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Levine Cancer Institute· Charlotte, NC

Related Studies